Table 2.

Treatment-emergent adverse events occurring in ≥10% of patients.

Dose CX-2029 (mg/kg)
0.10.250.512345All cohorts
Preferred term, n (%)(N = 3)(N = 3)(N = 6)(N = 3)(N = 8)(N = 12)(N = 6)(N = 4)(N = 45)
Patients with at least one treatment-emergent adverse event3 (100)3 (100)6 (100)3 (100)8 (100)12 (100)6 (100)4 (100)45 (100)
 IRR2 (67)3 (100)5 (83)3 (100)8 (100)9 (75)6 (100)3 (75)39 (87)
 Anemia002 (33)2 (67)7 (88)11 (92)5 (84)3 (75)30 (67)
 Nausea02 (67)3 (50)02 (25)5 (42)3 (50)1 (25)16 (36)
 Decreased appetite0001 (33)06 (50)3 (50)2 (50)12 (27)
 Fatigue001 (17)1 (33)2 (25)4 (33)2 (33)2 (50)12 (27)
 Constipation1 (33)2 (67)1 (17)01 (13)2 (17)1 (17)08 (18)
 Neutropenia002 (33)003 (25)1 (17)2 (50)8 (18)
 Vomiting1 (33)01 (17)004 (33)1 (17)1 (25)8 (18)
 Dyspnea01 (33)1 (17)01 (13)3 (25)01 (25)7 (16)
 Headache2 (67)01 (17)01 (13)01 (17)2 (50)7 (16)
 Dizziness0001 (33)03 (25)02 (50)6 (13)
 White blood cell count decreased000002 (17)2 (33)2 (50)6 (13)
 Aspartate aminotransferase increased00002 (25)2 (17)01 (25)5 (11)
 Asthenia000004 (33)01 (25)5 (11)
 Back pain1 (33)0001 (13)3 (25)005 (11)
 Neutrophil count decreased000001 (8)2 (33)2 (50)5 (11)